Stockreport

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Syndax Pharmaceuticals, Inc.  (SNDX) 
Last syndax pharmaceuticals, inc. earnings: 3/3 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.syndax.com
PDF – U.S. launch expected in early February –– Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drivers of inflammation [Read more]